Cargando…

GP2: The Global Parkinson's Genetics Program

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Regular Issue Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9290711/ https://www.ncbi.nlm.nih.gov/pubmed/33513272 http://dx.doi.org/10.1002/mds.28494

Ejemplares similares

Defining the causes of sporadic Parkinson’s disease in the global Parkinson’s genetics program (GP2)
por: Towns, Clodagh, et al.
Publicado: (2023)

Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2)
por: Lange, Lara M., et al.
Publicado: (2023)

Author Correction: Elucidating causative gene variants in hereditary Parkinson’s disease in the Global Parkinson’s Genetics Program (GP2)
por: Lange, Lara M., et al.
Publicado: (2023)

Accelerating Medicines Partnership: Parkinson's Disease. Genetic Resource
por: Iwaki, Hirotaka, et al.
Publicado: (2021)

Black and African American Connections to Parkinson's Disease Study: Addressing Missing Diversity in Parkinson's Disease Genetics
por: Bandres‐Ciga, Sara
Publicado: (2022)

Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions
por: Schumacher‐Schuh, Artur Francisco, et al.
Publicado: (2022)

Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy‐Parkinsonism From Parkinson's Disease
por: Quattrone, Andrea, et al.
Publicado: (2022)

The Impact of Type 2 Diabetes in Parkinson's Disease
por: Athauda, Dilan, et al.
Publicado: (2022)

Polycomb Repressive Complex 2 and KRYPTONITE regulate pathogen-induced programmed cell death in Arabidopsis
por: Dvořák Tomaštíková, Eva, et al.
Publicado: (2021)

Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk
por: Lake, Julie, et al.
Publicado: (2021)

The Parkinson's Disease DNA Variant Browser
por: Kim, Jonggeol J., et al.
Publicado: (2021)

The Myelin‐Weighted Connectome in Parkinson's Disease
por: Boshkovski, Tommy, et al.
Publicado: (2021)

Diabetes and Neuroaxonal Damage in Parkinson's Disease
por: Vijiaratnam, Nirosen, et al.
Publicado: (2022)

Solriamfetol for Excessive Daytime Sleepiness in Parkinson's Disease: Phase 2 Proof‐of‐Concept Trial
por: Videnovic, Aleksandar, et al.
Publicado: (2021)

Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson′s Disease
por: Coku, Ilda, et al.
Publicado: (2022)

A genetic approach reveals different modes of action of prefoldins
por: Blanco-Touriñán, Noel, et al.
Publicado: (2021)

Adenosine A(2A) Receptor Occupancy by Long‐Term Istradefylline Administration in Parkinson's Disease
por: Ishibashi, Kenji, et al.
Publicado: (2020)

Adenosine A(2A) Receptor Occupancy by Caffeine After Coffee Intake in Parkinson's Disease
por: Ishibashi, Kenji, et al.
Publicado: (2022)

Neuromelanin, aging, and neuronal vulnerability in Parkinson's disease
por: Vila, Miquel
Publicado: (2019)

Erratum to: A genetic approach reveals different modes of action of prefoldins
por: Blanco-Touriñán, Noel, et al.
Publicado: (2021)

Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor
por: Bright, Jessica M., et al.
Publicado: (2021)

De novo design of the global transcriptional factor Cra‐regulated promoters enables highly sensitive glycolysis flux biosensor for dynamic metabolic control
por: Zhu, Yuan, et al.
Publicado: (2022)

A Pooled Analysis From Phase 2b and 3 Studies in Japan of Istradefylline in Parkinson's Disease
por: Hattori, Nobutaka, et al.
Publicado: (2020)

Differential Phospho‐Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease
por: Garrido, Alicia, et al.
Publicado: (2022)

A Multi‐Step Model of Parkinson's Disease Pathogenesis
por: Le Heron, Campbell, et al.
Publicado: (2021)

Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity
por: Omer, Nurit, et al.
Publicado: (2021)

Orthostatic Hypotension: A Prodromal Marker of Parkinson's Disease?
por: Dommershuijsen, Lisanne J., et al.
Publicado: (2020)

Neuroimaging of Anxiety in Parkinson's Disease: A Systematic Review
por: Carey, Guillaume, et al.
Publicado: (2020)

Neuroimaging in Glucocerebrosidase‐Associated Parkinsonism: A Systematic Review
por: Filippi, Massimo, et al.
Publicado: (2022)

Parkinson's Disease Phenotypes in Patient Neuronal Cultures and Brain Organoids Improved by 2‐Hydroxypropyl‐β‐Cyclodextrin Treatment
por: Jarazo, Javier, et al.
Publicado: (2021)

Development of genetic tools for heterologous protein expression in a pentose‐utilizing environmental isolate of Pseudomonas putida
por: Gauttam, Rahul, et al.
Publicado: (2023)

Cerebello‐Cortical Control of Tremor Rhythm and Amplitude in Parkinson's Disease
por: Helmich, Rick C., et al.
Publicado: (2021)

Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity
por: Werner, Milton H., et al.
Publicado: (2021)

MIND and Mediterranean Diets Associated with Later Onset of Parkinson's Disease
por: Metcalfe‐Roach, Avril, et al.
Publicado: (2021)

Cytokines and Gaucher Biomarkers in Glucocerebrosidase Carriers with and Without Parkinson Disease
por: Galper, Jasmin, et al.
Publicado: (2021)

Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter?
por: Campese, Nicole, et al.
Publicado: (2021)

Preexisting Bipolar Disorder Influences the Subsequent Phenotype of Parkinson's Disease
por: Onofrj, Marco, et al.
Publicado: (2021)

Self‐Report versus Clinician Examination in Early Parkinson's Disease
por: Zolfaghari, Sheida, et al.
Publicado: (2021)

Long‐Term Safety and Clinical Effects of Nilotinib in Parkinson's Disease
por: Pagan, Fernando L., et al.
Publicado: (2020)

Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease
por: Heilman, Patrick L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ff035c853v8aramgg9a66u972h